文献速递心律失常

N末端B型利钠肽原在房颤系统筛查中的应用

N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation.
PubMed 文献 · Heart · 2017-03-02

本研究基于Strokestop研究,对886名75/76岁瑞典居民检测NT-proBNP。新检出房颤者(n=96)NT-proBNP中位数330 ng/L,无房颤者(n=742)为171 ng/L,p<0.001。以NT-proBNP≥125 ng/L为切点,阴性预测值92%,可减少35%的筛查人数。作者认为需前瞻性研究明确NT-proBNP能否用于选择最受益于房颤筛查的人群。

要点

  • 新检出房颤者NT-proBNP中位数330 ng/L,高于无房颤者的171 ng/L。
  • NT-proBNP≥125 ng/L在非急性 setting 阴性预测值92%,可减少35%筛查人数。
  • 联合体重可进一步减少筛查人数并保持敏感性。

核心结论

  • 新检出房颤者NT-proBNP升高,作者认为需前瞻性研究明确其能否用于选择最受益于房颤筛查的人群。

研究设计与样本

  • Strokestop研究纳入7173名75/76岁瑞典居民,采用每日两次间断心电图记录2周筛查房颤;本亚组研究检测886名参与者的NT-proBNP,包括最后815名连续参与者及71名新检出房颤者。

主要发现

  • 新检出房颤者(n=96)NT-proBNP中位数为330 ng/L(IQR 121;634),无房颤者(n=742)为171 ng/L(IQR 95;283),p<0.001。
  • 新检出房颤者与无房颤者之间、以及NT-proBNP队列中新检出房颤者与未检测NT-proBNP队列中新检出房颤者之间,CHA2DS2-VASc参数均无显著差异。
  • 在非急性 setting 以NT-proBNP≥125 ng/L为切点,阴性预测值为92%,应用于系统房颤筛查时可减少35%的筛查人数。
  • 联合体重可进一步减少需筛查人数并保持敏感性。

关键数值与推荐

  • NT-proBNP切点≥125 ng/L在非急性 setting 的阴性预测值为92%,可减少35%的筛查人数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Screening for atrial fibrillation (AF) in individuals aged 65 and above is recommended by the European Society of Cardiology. Increased levels of the biomarker N-terminal pro B-type natriuretic peptide (NT-proBNP) has in cohort studies been associated with incident AF.The aim of this study was to assess whether NT-proBNP could be useful for AF detection in systematic screening. METHODS: The Strokestop study entailed 7173 Swedish residents aged 75/76 that were screened for AF using twice daily intermittent ECG recordings during 2 weeks. In a substudy of 886 participants, the last 815 consecutive participants and 71 individuals with newly detected AF, levels of NT-proBNP were determined. RESULTS: Participants with newly detected AF (n=96) had a median NT-proBNP of 330 ng/L (IQR 121;634). In individuals without AF (n=742), median NT-proBNP was 171 ng/L (IQR 95;283), p<0.001. The CHA2DS2-VASc parameters did not differ significantly between individuals with newly detected AF and without AF nor between newly detected AF in the NT-proBNP cohort compared with the cohort where NT-proBNP was not assessed. Using an NT-proBNP cut-off of ≥125 ng/L in a non-acute setting yielded a negative predictive value of 92%, meaning that 35% fewer participants would need to be screened when applied to systematic AF screening. Adding weight to NT-proBNP further reduced participants needed to be screened with a preserved sensitivity. CONCLUSIONS: NT-proBNP was increased in individuals with newly detected AF. Prospective studies could clarify if NT-proBNP can be used to correctly select individuals that benefit most from AF screening. CLINICAL TRIALS: ClinicalTrials.gov. Identifier: NCT01593553.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Svennberg E, Henriksson P, Engdahl J, et al. N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation. Heart. 2017. PMID: 28255099. doi:10.1136/heartjnl-2016-310236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。